References

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting

10.1016/j.clinthera.2011.04.010 · 2011 · External reference

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

10.1200/jco.2004.09.059 · 2004 · External reference

Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan

10.1016/j.jval.2011.01.010 · 2011 · External reference

NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy

10.1016/s1470-2045(12)70044-x · 2012 · External reference

Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial

10.1016/j.jval.2011.10.006 · 2012 · External reference

Cetuximab for the treatment of colorectal cancer

10.1056/nejmoa071834 · 2007 · External reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer

10.1056/nejmoa0804385 · 2008 · External reference

A genetic model for colorectal tumorigenesis

10.1016/0092-8674(90)90186-i · 1990 · External reference

Serrated polyps and colorectal cancer: new pathway to malignancy

10.1146/annurev.pathol.4.110807.092317 · 2009 · External reference

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

10.1056/nejmoa022289 · 2003 · External reference

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy

10.1093/jnci/djr153 · 2011 · External reference

A novel putative tyrosine kinase receptor encoded by the eph gene

10.1126/science.2825356 · 1987 · External reference

The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration

10.1016/s0092-8674(01)00191-x · 2001 · External reference

Integrins: versatility, modulation, and signaling in cell adhesion

10.1016/0092-8674(92)90115-s · 1992 · External reference

EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase

10.1016/s1097-2765(02)00488-4 · 2002 · External reference

Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis

10.1007/s00018-003-2297-3 · 2003 · External reference

Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrinB2 and its receptor Eph-B4

10.1016/s0092-8674(00)81436-1 · 1998 · External reference

Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors

10.1158/0008-5472.can-05-2580 · 2005 · External reference

EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers

10.1158/1078-0432.ccr-04-2458 · 2005 · External reference

The role of ephrins and Eph receptors in cancer

10.1016/j.cytogfr.2004.09.002 · 2004 · External reference

EphB receptor activity suppresses colorectal cancer progression

10.1038/nature03626 · 2005 · External reference

The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse

10.1016/j.stem.2011.02.020 · 2011 · External reference

EphB2 is a prognostic factor in colorectal cancer

10.1158/1078-0432.ccr-05-0143 · 2005 · External reference

Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors

10.5858/arpa.2010-0560-oa · 2011 · External reference

A method for checking regression models in survival analysis based on the risk score

10.1007/bf00127305 · 1996 · External reference

Unresolved reference

External reference

Prognostic significance of ephrin B2 and microsatellite status in stage III colon cancer

2010 · External reference

Validation of tissue microarray technology in breast carcinoma

10.1038/labinvest.3780204 · 2000 · External reference